Dianthus Therapeutics opened lower at $88.12, compared with its previous close of $89.30. In the last trading session, the stock traded between $83.84 and $92.79. It showed an upward intraday trend.
An investment of $100 made 4 years ago in Dianthus Therapeutics is now worth
$ 841.87
Giving a profit of
$ 741.87 (741.87%)
Note: Past profits do not guarantee future returns.
Rating from 9 Analysts
Today's Change
+$3.31 (+3.70%)
Day High
$92.79
Day Low
$83.84
Day Open
$88.12
Prev Close
$89.30
Volume
7,43,498
1W Return
8.05%
1M Return
13.68%
3M Return
-14.58%
6M Return
6.30%
1Y Return
156.53%
Market Cap ($ Mn)
5,215
PE Ratio
-
PB Ratio
4.95
PEG Ratio
-
ROE
-40.10%
ROCE
-43.59%
EPS (TTM)
-
1 Week
8.05%
1 Month
13.68%
3 Months
-14.58%
6 Months
6.30%
9 Months
85.51%
Dianthus Therapeutics grants stock options to three new hires
Granted non-qualified stock options for 26,000 shares. Exercise price set at $82.25 per share. Awards issued to three newly hired non-executive employees. Grants approved under Nasdaq Listing Rule 5635(c)(4).
10 days agoHC Wainwright reiterates Buy on Dianthus Therapeutics with $158 target
HC Wainwright & Co. reiterated a Buy rating on Dianthus Therapeutics. Analyst Swayampakula Ramakanth maintained a $158 price target. The action reflects continued confidence in the company's outlook.
28 days agoDianthus Therapeutics grants 52,000 stock options to new hires
Dianthus Therapeutics granted 52,000 stock options to four new employees. Exercise price set at $106.62 per share with a 10-year term. Awards vest 25% after one year, then monthly over 36 months. Grants approved under Nasdaq Listing Rule 5635(c)(4).
2mo agoDianthus Therapeutics grants 87,000 options at $106.02 to six new hires
Dianthus Therapeutics, Inc. granted 87,000 non-qualified stock options to six new employees on August 3, 2026. The options have an exercise price of $106.02 per share and a 10-year term, vesting over four years. The awards were approved under Nasdaq Listing Rule 5635(c)(4) to serve as material inducements for employment.
3mo agoDianthus Therapeutics grants 58,000 options to new hires
Dianthus Therapeutics, Inc. granted 58,000 stock options to five new employees on July 1, 2026, with an exercise price of $90.21 per share. The options, approved by the independent Compensation Committee under Nasdaq Listing Rule 5635(c)(4), vest over four years. The awards aim to induce employment and are governed by the company's Equity Inducement Plan.
4mo agoDianthus Therapeutics stock rises on strong CIDP trial data
Dianthus Therapeutics Inc. saw its stock increase by 7.57% to $82.24 after reporting a 75% confirmed responder rate in the Part A interim analysis of its CAPTIVATE Phase 3 trial for claseprubart in CIDP patients. The drug showed a clean safety profile with no serious adverse events. William Blair maintained an Outperform rating, suggesting the data alleviates concerns about the C1s inhibitor class and positions claseprubart favorably against competitors.
5mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 4 years ago in Dianthus Therapeutics is now worth
$ 841.87
Giving a profit of
$ 741.87 (741.87%)
Note: Past profits do not guarantee future returns.
